Orchestra BioMed
Orchestra BioMed's revenue rose 1169.2% to $34 million in fiscal 2025. Its operating margin was −154.7%, up from −2,437.5% a year earlier. Free cash flow was −$49 million. The diluted share count rose 29.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Orchestra BioMed does
Orchestra BioMed is a biomedical company that develops heart and blood vessel treatments with partners that are large medical device makers. It was formed in 2018 around a set of late-stage product candidates from its founders. It has no approved products and has limited sources of revenue.
Its two flagship candidates are Atrioventricular Interval Modulation Therapy, or AVIM, for high blood pressure, and Virtue Sirolimus AngioInfusion Balloon, a drug-delivering balloon for clogged arteries. AVIM works as a software update to a standard cardiac pacemaker. It has an exclusive license and collaboration agreement with Medtronic to develop and sell AVIM for uncontrolled high blood pressure in patients who need a pacemaker, and a pivotal study called BACKBEAT is enrolling patients.
For Virtue, it has started enrolling patients in a U.S. pivotal trial, which compares it with Boston Scientific's AGENT drug-coated balloon for blocked stents. The company says it shares risks and rewards with its partners.
Its biggest risks, as it describes them
- It has lost money since it began and may never be profitable.
- It may need substantial additional funding to continue developing its products.
- Its clinical studies could fail or be delayed, which could stop its devices from being approved.
- It depends on partners such as Medtronic to develop and sell its products.
- It competes with much larger companies.
Income statement
Orchestra BioMed lost money in fiscal 2025: a net loss of $53 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 2 | 84 | 88 | 67 | 106 |
| Debt incl. finance leases | — | — | — | 15 | 15 |
| Net debt (negative means net cash) | — | — | — | −52 | −92 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.5x | 0.3x |
| Interest coverage | — | −25.1x | −36.8x | −216.5x | −35.8x |
| Current ratio | 10.9x | 4.6x | 8.0x | 4.3x | 6.5x |
| Quick ratio | 10.9x | 4.5x | 7.9x | 4.3x | 6.4x |
Cash flow
Projections
Project Orchestra BioMed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $259,541 of Orchestra BioMed shares on the open market, and 2 insiders sold $257,682, $257,550 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | David P HochmanSee Remarks, Director | Bought | 10,000 | $4.79 | $47,900 | Form 4 |
| Sep 1, 2026 | Darren ShermanSee Remarks, Director | Sold plan | 15,000 | $4.94 | $74,100 | Form 4 |
| Aug 26, 2026 | Darren ShermanSee Remarks, Director | Bought | 2,000 | $5.33 | $10,660 | Form 4 |
| Aug 3, 2026 | Darren ShermanSee Remarks, Director | Sold plan | 15,000 | $4.09 | $61,350 | Form 4 |
| Jul 1, 2026 | Darren ShermanSee Remarks, Director | Sold plan | 15,000 | $4.27 | $64,050 | Form 4 |
| Jun 1, 2026 | Darren ShermanSee Remarks, Director | Sold plan | 15,000 | $3.87 | $58,050 | Form 4 |
| Jun 1, 2026 | David P HochmanSee Remarks, Director | Bought | 5,000 | $3.83 | $19,150 | Form 4 |
| May 18, 2026 | Jason AryehDirector | Bought | 665 | $3.75 | $2,494 | Form 4 |
| May 15, 2026 | Jason AryehDirector | Bought | 8,971 | $3.90 | $34,987 | Form 4 |
| May 15, 2026 | David P HochmanSee Remarks, Director | Bought | 5,000 | $3.77 | $18,850 | Form 4 |
| May 14, 2026 | Eric S FainDirector | Bought | 20,000 | $4.13 | $82,600 | Form 4 |
| Apr 27, 2026 | Rtw Investments Lp10% owner | Sold | 32 | $4.13 | $132 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 5 of 9 |
| Rule of 40 | −1,696.0% | −1,931.9% | 1,021.5% |
| Altman Z'' | −4.16 | −13.57 | −7.02 |
| Accruals ratio | −3.1% | −12.2% | −3.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | 5 of 9 |
Compare
Put Orchestra BioMed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Orchestra BioMed | FY25 | 1,169.2% | −154.7% | −147.7% | — | — | 5 | |
| Stereotaxis | FY25 | 20.3% | −68.3% | −42.5% | — | — | — | Compare |
| electroCore | FY25 | 27.2% | −41.1% | −25.8% | — | — | — | Compare |
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | Compare |
| Precision Optics Corporation | FY26 | 65.2% | −11.1% | −6.3% | −22.8% | — | 5 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | 4 | 3 | 3 | 34 |
| Revenue growth | — | — | −21.9% | −4.4% | 1,169.2% |
| Gross profit | — | 3 | 3 | 2 | 33 |
| Research and development | — | 22 | 34 | 43 | 58 |
| Operating income | −0 | −33 | −52 | −64 | −52 |
| Net income | −0 | −34 | −49 | −61 | −53 |
| Diluted EPS (US$) | −0.02 | −2.24 | −1.48 | −1.66 | −1.11 |
| Diluted shares (millions) | 20 | 15 | 33 | 37 | 48 |
| Cash flow | |||||
| Cash from operations | −0 | −29 | −46 | −51 | −49 |
| Capital expenditure | — | 1 | 0 | 0 | 0 |
| Free cash flow | — | −30 | −46 | −51 | −49 |
| Dividends paid | 0 | 20 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 3 | 8 | 11 | 12 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 2 | 84 | 88 | 67 | 106 |
| Debt incl. finance leases | — | — | — | 15 | 15 |
| Total assets | 162 | 96 | 95 | 76 | 115 |
| Total liabilities | 6 | 43 | 27 | 43 | 52 |
| Shareholders' equity | −4 | −7 | 68 | 33 | 54 |
| Margins and ratios | |||||
| Gross margin | — | 94.0% | 93.3% | 92.3% | 99.4% |
| Operating margin | — | −924.3% | −1,866.2% | −2,437.5% | −154.7% |
| Net margin | — | −951.3% | −1,779.7% | −2,313.3% | −157.4% |
| Free cash flow margin | — | −845.7% | −1,674.1% | −1,927.5% | −147.7% |
| Rule of 40 (growth + FCF margin) | — | — | −1,696.0% | −1,931.9% | 1,021.5% |
| Return on capital | — | — | — | — | — |
| Return on equity | — | — | −160.8% | −120.8% | −121.8% |
| Return on assets | — | −26.1% | −51.5% | −71.2% | −55.2% |
| Net debt to EBITDA | — | — | — | — | — |